导航
| 统计阶段 | 收益率 | 同类排名 |
|---|---|---|
| 今年以来 | 1.85% | 1979/4773 |
| 近一周 | -1.88% | 3059/5465 |
| 近一月 | -0.96% | 979/5421 |
| 近一季 | -3.80% | 1689/5231 |
| 近半年 | -7.52% | 3361/4920 |
| 近一年 | 5.66% | 1679/4394 |
| 近两年 | 28.09% | 2367/2954 |
| 近三年 | 18.72% | 1539/2253 |
| 成立以来 | 93.19% | - |
| 年份 | 年收益 | 1季度 | 2季度 | 3季度 | 4季度 |
| 2026 | - - |
3.38% 738/4961 |
1.67% 3001/5312 |
- - |
- - |
| 2025 | 6.65% 2954/4813 |
-4.46% 3178/3635 |
1.01% 2501/4076 |
7.05% 3483/4524 |
3.23% 714/4813 |
| 2024 | 16.70% 775/3463 |
9.06% 151/2808 |
2.12% 394/3014 |
6.19% 2865/3129 |
-1.33% 1656/3463 |
| 2023 | 6.47% 168/2656 |
15.33% 212/2280 |
1.09% 241/2385 |
-3.20% 864/2515 |
-5.66% 1449/2655 |
| 2022 | -13.30% 324/2207 |
-10.99% 469/1919 |
2.49% 1296/2016 |
-9.54% 288/2113 |
5.07% 489/2208 |
| 2021 | 25.99% 103/1822 |
2.67% 213/1255 |
3.65% 963/1330 |
16.86% 72/1466 |
1.31% 967/1822 |
| 2020 | 14.90% 786/1250 |
-6.09% 456/1028 |
0.42% 1004/1067 |
10.14% 583/1164 |
10.62% 589/1184 |
| 2019 | - - |
- - |
- - |
- - |
- - |
| 2018 | - - |
- - |
- - |
- - |
- - |
| 2017 | - - |
- - |
- - |
- - |
- - |
| 2016 | - - |
- - |
- - |
- - |
- - |
| 2015 | - - |
- - |
- - |
- - |
- - |
| 2014 | - - |
- - |
- - |
- - |
- - |
| 2013 | - - |
- - |
- - |
- - |
- - |
| 2012 | - - |
- - |
- - |
- - |
- - |
| 基金名称 | 最新净值 | 季增长率 |
| 万家中证港股通创新药ETF | 1.5896 | 28.31% |
| 港股医疗ETF | 1.4282 | 28.15% |
| 天弘恒生沪深港创新药精选50ETF | 0.8437 | 27.35% |
| 华富中证港股通创新药指数型发起式A | 1.1464 | 27.24% |
| 嘉实中证港股通创新药指数发起式C | 0.8441 | 26.80% |
| 中欧中证港股通创新药指数发起A | 1.5868 | 26.75% |
| 中欧中证港股通创新药指数发起C | 1.4370 | 26.67% |
| 永赢中证港股通医疗主题ETF发起联接A | 0.8762 | 26.58% |
| 华夏中证港股通医疗主题ETF发起式联接A | 0.8585 | 26.45% |
| 华夏中证港股通医疗主题ETF发起式联接C | 0.8568 | 26.39% |
| 广发央企创新驱动ETF联接C VS. 长安沪深300非周期A(740101) |